NYSE$LH

Laboratory Corp Of America Holdings · Q3 2023 earnings

Q3 2023 earnings · · Investor relations

Briefing

Labcorp's third quarter results were released, showing revenue growth driven by the Base Business and advancements in specialty testing capabilities.

Labcorp announced strong third quarter results, with revenue increasing by 6.6% to $3.06 billion, driven by 14.0% growth in the Base Business. Diluted EPS was reported at $2.11, and adjusted EPS reached $3.38. The company updated its full-year guidance, projecting adjusted EPS of $13.25 to $13.75 and free cash flow of $0.85 billion to $0.95 billion.

  • Revenue increased by 6.6% compared to the previous year, reaching $3.06 billion.
  • Base Business grew by 14.0%, offsetting a decrease in COVID-19 testing revenue.
  • Diluted EPS was $2.11, while adjusted EPS was $3.38.
  • Full-year guidance updated with adjusted EPS projected between $13.25 and $13.75 and free cash flow between $0.85 billion and $0.95 billion.

Headline financials

Total Revenue

$3.06B

Previous: $3.61B-15.2%
EPS (adj)

$3.38

Previous: $4.68-27.8%
TTM Net Orders

$3.05B

No prior period
TTM Book-to-Bill

1.12

Previous: 1.25-10.4%
Backlog

$7.79B

Previous: $15.3B-48.9%
Capital Expenditures

-$286M

Previous: -$364M+21.3%
Free Cash Flow

-$103M

Previous: -$11.2M-820.5%
Net Income

$183M

Previous: $353M-48.0%
Operating Income

$252M

Previous: $469M-46.3%
Gross Profit

$851M

Previous: $1.06B-19.7%
Cash & Equivalents

$728M

Previous: $410M+77.6%
Total Assets

$16.9B

Previous: $19.8B-14.8%
Stock-Based Comp

$34.4M

Previous: $36.3M-5.2%

Revenue & EPS history

LabCorp · Revenue · Quarterly

$3.06B

Q3 2023-15.2%vs Q3 2022
Beat estimate in 8 of 15 quarters(53%)
ActualEstimate

Revenue by segment

LabCorp · $3.06B total across 2 segments · Q3 2023

  • Diagnostics Laboratories
    $2.34B+6.0%
  • Biopharma Laboratory Services
    $719M-48.8%

Forward guidance

Labcorp is updating 2023 full year guidance to reflect its third quarter performance and full year outlook.

Tailwinds

  • 2023 Guidance includes an impact from foreign currency translation of 0.2%
  • Base Business 2023 Guidance includes an impact from foreign currency translation of 0.2%
  • Total Diagnostics Laboratories 2023 Guidance includes an impact from foreign currency translation of (0.1%)
  • Total Biopharma Lab Services 2023 Guidance includes an impact from foreign currency translation of 1.3%
  • Free cash flow from continuing operations excluding spin-related items

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2023

Historical avgQ3 2023

-0.3%

Avg return

Earnings day

-0.6%

Avg return

5 days after

-0.9%

Avg return

30 days after

48%

35 / 73 earnings

Positive

+9.5%

Q2 2024

Best reaction

-10.4%

Q3 2016

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-3.0%+0.0%+1.3%
Q4 2025-2.1%+0.0%-6.6%
Q3 2025-5.7%-7.9%-2.7%
Q2 2025-0.5%+1.2%+2.0%
Q1 2025+4.7%+7.9%+7.5%
Q4 2024-0.9%-1.9%+1.2%
Q3 2024+4.0%+3.7%+9.0%
Q2 2024+9.5%+4.8%+6.7%
Q1 2024-4.6%-3.2%-4.0%
Q4 2023-5.0%-5.5%-8.3%
Q3 2023+0.6%+1.0%+7.6%
Q2 2023-1.9%-2.4%-3.0%
Q1 2023-4.6%-2.5%-8.2%
Q4 2022+3.2%-0.4%-14.1%
Q3 2022-2.5%-3.2%+5.0%
Q2 2022+5.1%+1.2%-8.1%
Q1 2022-5.0%-3.1%+1.9%
Q4 2021-1.9%-6.0%-5.7%
Q3 2021+2.3%+2.0%+3.1%
Q2 2021+4.6%+6.0%+6.1%
Q1 2021+1.2%+4.1%+4.5%
Q4 2020+4.0%+3.1%+4.1%
Q3 2020+1.0%-1.1%-2.7%
Q2 2020-3.3%-4.2%-13.4%
Q1 2020-6.5%-10.4%-0.4%
Q4 2019+4.1%+1.8%-19.5%
Q3 2019-2.0%-2.3%+0.4%
Q2 2019-6.5%-4.2%-6.9%
Q1 2019+3.7%+6.1%+5.1%
Q4 2018+2.5%+3.8%+3.7%
Q3 2018-7.1%-6.2%-4.1%
Q2 2018-5.4%-6.4%-5.3%
Q1 2018+3.9%+2.8%+9.7%
Q4 2017+3.9%+3.0%+5.9%
Q3 2017+1.7%+2.2%+0.2%
Q2 2017+2.0%+1.3%-1.4%
Q1 2017-4.1%-3.1%-1.9%
Q4 2016+2.4%+2.4%+5.4%
Q3 2016-10.4%-9.4%-7.9%
Q2 2016+0.4%+1.2%-1.4%
Q1 2016+4.1%
Q4 2015+2.8%
Q3 2015+7.8%
Q2 2015+3.8%
Q1 2015-2.7%
Q4 2014+4.9%
Q3 2014+3.5%
Q2 2014-0.5%
Q1 2014-0.7%
Q4 2013+1.1%
Q3 2013-3.2%
Q2 2013+0.0%
Q1 2013+0.7%
Q4 2012-1.7%
Q3 2012-4.0%
Q2 2012-9.0%
Q1 2012-3.4%
Q4 2011+2.2%
Q3 2011-6.6%
Q2 2011-0.6%
Q1 2011+1.4%
Q4 2010-0.2%
Q4 2007-0.2%
Q3 2010+1.6%
Q2 2010+0.9%
Q1 2009+1.8%
Q1 2010+1.6%
Q4 2009-0.4%
Q2 2008-1.6%
Q3 2009-1.6%
Q3 2008-1.6%
Q4 2008-1.4%
Q2 2009-1.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro